Biomark Diagnostics Inc. (FRA:20B)

Germany · Delayed Price · Currency is EUR

0.278

+0.012 (4.51%)

Last updated: Dec 4, 2025, 3:43 PM CET

122.40% (1Y)

Market Cap	29.22M
Revenue (ttm)	75.52K
Net Income (ttm)	-1.01M
Shares Out	105.09M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	10
Open	0.270
Previous Close	0.266
Day's Range	0.270 - 0.278
52-Week Range	0.099 - 0.278
Beta	-0.21
RSI	75.22
Earnings Date	Nov 27, 2025

About Biomark Diagnostics

Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada. [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2014

Country Canada

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 20B

Full Company Profile

Financial Performance

In 2024, Biomark Diagnostics's revenue was 154,216, a decrease of -5.52% compared to the previous year's 163,220. Losses were -1.93 million, 35.0% more than in 2023.

Financial numbers in CAD Financial Statements

News

There is no news available yet.